Adherence to follow-up after a positive fecal occult blood test in an organized colorectal cancer screening program in Korea, 2004-2008

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 6, 2012, Pages 1070-1077

  Choi, Kui Son ^a   Lee, Hoo Yeon ^b   Jun, Jae Kwan ^a   Shin, Aesun ^a   Park, Eun Cheol ^c  

^a National Cancer Center   (South Korea)

^b Dankook University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Colonoscopy; Colorectal cancer; Double contrast barium enema; Fecal occult blood test; Screening

Indexed keywords

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; BARIUM ENEMA; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; DOUBLE CONTRAST RADIOGRAPHY; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NATIONAL HEALTH INSURANCE; OCCULT BLOOD TEST; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEX DIFFERENCE; SOUTH KOREA;

EID: 84861464935     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06944.x     Document Type: Article

References (39)

1. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin DM. GLOBALCAN 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer, 2010.
2. Stewart BW, Kleihues P. World Cancer Report. Lyon, France: International Agency for Research on Cancer, 2003.
3. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 2001; 37 (Suppl. 8): S4-66.
4. Jung KW, Park S, Kong HJ etal. Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J. Korean Med. Sci. 2010; 25: 1113-21.
5. Mandel JS, Bond JH, Church TR etal. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota colon cancer control study. N. Engl. J. Med. 1993; 328: 1365-71.
6. Mandel JS, Church TR, Bond JH etal. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N. Engl. J. Med. 2000; 343: 1603-7.
7. Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM. Screening sigmoidoscopy and colorectal cancer mortality. J. Natl Cancer Inst. 1992; 84: 1572-5.
8. Selby JV, Friedman GD, Quesenberry CP, Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N. Engl. J. Med. 1992; 326: 653-7.
9. Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW. Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J. Clin. 2010; 60: 99-119.
10. U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Service Task Force recommendation statement. Ann. Intern. Med. 2008; 149: 627-37.
11. Sung JJ, Lau JY, Young GP etal. Asia Pacific consensus recommendations for colorectal cancer screening. Gut 2008; 57: 1166-76.
12. Yoo KY. Cancer control activities in the Republic of Korea. Jpn J. Clin. Oncol. 2008; 38: 327-33.
13. Towler BP, Irwig L, Glasziou P, Weller D, Kewenter J. Screening for colorectal cancer using the faecal occult blood test, hemoccult. Cochrane Database Syst. Rev. 2000; (2): CD001216.
14. Gatto NM, Frucht H, Sundararajan V, Jacobson JS, Grann VR, Neugut AI. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J. Natl Cancer Inst. 2003; 95: 230-6.
15. Winawer SJ, Fletcher RH, Miller L etal. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997; 112: 594-642.
16. Winawer SJ. Screening sigmoidoscopy: can the road to colonoscopy be less traveled? Ann. Intern. Med. 2003; 139: 1034-5.
17. Hardcastle JD, Chamberlain JO, Robinson MH etal. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472-7.
18. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467-71.
19. Kewenter J, Brevinge H, Engaras B, Haglind E, Ahren C. Follow-up after screening for colorectal neoplasms with fecal occult blood testing in a controlled trial. Dis. Colon Rectum 1994; 37: 115-19.
20. Carlson CM, Kirby KA, Casadei MA, Partin MR, Kistler CE, Walter LC. Lack of follow-up after fecal occult blood testing in older adults: inappropriate screening or failure to follow up? Arch. Intern. Med. 2011; 171: 249-56.
21. Etzioni DA, Yano EM, Rubenstein LV etal. Measuring the quality of colorectal cancer screening: the importance of follow-up. Dis. Colon Rectum 2006; 49: 1002-10.
22. Fisher DA, Jeffreys A, Coffman CJ, Fasanella K. Barriers to full colon evaluation for a positive fecal occult blood test. Cancer Epidemiol. Biomarkers Prev. 2006; 15: 1232-5.
23. Goulard H, Boussac-Zarebska M, Ancelle-Park R, Bloch J. French colorectal cancer screening pilot programme: results of the first round. J. Med. Screen. 2008; 15: 143-8.
24. Miglioretti DL, Rutter CM, Bradford SC etal. Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization. Med. Care 2008; 46: S91-6.
25. Turner B, Myers RE, Hyslop T etal. Physician and patient factors associated with ordering a colon evaluation after a positive fecal occult blood test. J. Gen. Intern. Med. 2003; 18: 357-63.
26. Steele RJ, McClements PL, Libby G etal. Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer. Gut 2009; 58: 530-5.
27. Weller DP, Owen N, Hiller JE, Willson K, Wilson D. Colorectal cancer and its prevention: prevalence of beliefs, attitudes, intentions and behaviour. Aust. J. Public Health 1995; 19: 19-23.
28. Grazzini G, Ciatto S, Cislaghi C etal. Cost evaluation in a colorectal cancer screening programme by faecal occult blood test in the district of Florence. J. Med. Screen. 2008; 15: 175-81.
29. Vernon SW. Participation in colorectal cancer screening: a review. J. Natl Cancer Inst. 1997; 89: 1406-22.
30. Lafata JE, Williams LK, Ben-Menachem T, Moon C, Divine G. Colorectal carcinoma screening procedure use among primary care patients. Cancer 2005; 104: 1356-61.
31. Seeff LC, Nadel MR, Klabunde CN etal. Patterns and predictors of colorectal cancer test use in the adult U.S. population. Cancer 2004; 100: 2093-103.
32. Meissner HI, Breen N, Klabunde CN, Vernon SW. Patterns of colorectal cancer screening uptake among men and women in the United States. Cancer Epidemiol. Biomarkers Prev. 2006; 15: 389-94.
33. Moss SM, Campbell C, Melia J etal. Performance measures in three rounds of the English bowel cancer screening pilot. Gut 2011; doi 10.1136/gut.2010.236430.
34. Baig N, Myers RE, Turner BJ etal. Physician-reported reasons for limited follow-up of patients with a positive fecal occult blood test screening result. Am. J. Gastroenterol. 2003; 98: 2078-81.
35. Myers RE, Fishbein G, Hyslop T etal. Measuring complete diagnostic evaluation in colorectal cancer screening. Cancer Detect. Prev. 2001; 25: 174-82.
36. UK, Group CCSP. Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. BMJ 2004; 329: 133-5.
37. Lee BH, Jeong SY. Korean national recommendation guidelines on screening and surveillance for early detection of colorectal cancers. J Korean Med Assoc 2002; 45: 981-91.
38. Cooper GS, Fortinsky RH, Hapke R, Landefeld CS. Primary care physician recommendations for colorectal cancer screening. Patient and practitioner factors. Arch. Intern. Med. 1997; 157: 1946-50.
39. Janz NK, Lakhani I, Vijan S, Hawley ST, Chung LK, Katz SJ. Determinants of colorectal cancer screening use, attempts, and non-use. Prev. Med. 2007; 44: 452-8.